JP2008531746A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531746A5 JP2008531746A5 JP2008500768A JP2008500768A JP2008531746A5 JP 2008531746 A5 JP2008531746 A5 JP 2008531746A5 JP 2008500768 A JP2008500768 A JP 2008500768A JP 2008500768 A JP2008500768 A JP 2008500768A JP 2008531746 A5 JP2008531746 A5 JP 2008531746A5
- Authority
- JP
- Japan
- Prior art keywords
- tweak
- antibody
- receptor
- tweak receptor
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 21
- 108010014401 TWEAK Receptor Proteins 0.000 claims 18
- 102000016946 TWEAK Receptor Human genes 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 102000005962 receptors Human genes 0.000 claims 9
- 108020003175 receptors Proteins 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000004068 intracellular signaling Effects 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101000830598 Homo sapiens Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims 2
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 102000058177 human TNFSF12 Human genes 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- -1 radiation Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65933905P | 2005-03-07 | 2005-03-07 | |
| PCT/US2006/007547 WO2006096487A2 (en) | 2005-03-07 | 2006-03-02 | Methods and compositions for modulating tweak and fn14 activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013271694A Division JP2014111605A (ja) | 2005-03-07 | 2013-12-27 | Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008531746A JP2008531746A (ja) | 2008-08-14 |
| JP2008531746A5 true JP2008531746A5 (cg-RX-API-DMAC7.html) | 2009-04-16 |
Family
ID=36953868
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008500768A Withdrawn JP2008531746A (ja) | 2005-03-07 | 2006-03-02 | Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物 |
| JP2013271694A Pending JP2014111605A (ja) | 2005-03-07 | 2013-12-27 | Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013271694A Pending JP2014111605A (ja) | 2005-03-07 | 2013-12-27 | Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20080286271A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1853312B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2008531746A (cg-RX-API-DMAC7.html) |
| KR (3) | KR20130089271A (cg-RX-API-DMAC7.html) |
| CN (2) | CN101171035A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006220825A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0608012A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2597485A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL185180A0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2007137060A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006096487A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200707489B (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0105044A3 (en) | 1999-01-15 | 2004-07-28 | Biogen Inc Cambridge | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| AU2003224950B2 (en) | 2002-04-09 | 2006-09-14 | Biogen Ma Inc. | Methods for treating tweak-related conditions |
| DK2332408T3 (da) | 2005-02-17 | 2013-12-02 | Biogen Idec Inc | Behandling af neurologiske sygdomme |
| WO2006088890A2 (en) * | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating stroke |
| KR20130089271A (ko) * | 2005-03-07 | 2013-08-09 | 제넨테크, 인크. | Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물 |
| WO2006122187A2 (en) * | 2005-05-10 | 2006-11-16 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| NZ583636A (en) | 2005-05-27 | 2011-12-22 | Biogen Idec Inc | Tweak binding antibodies |
| WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| US20100284933A1 (en) * | 2006-10-16 | 2010-11-11 | Biogen Idec Ma Inc. | Biomarkers of Multiple Sclerosis |
| MX2010001378A (es) * | 2007-08-03 | 2010-06-02 | Facet Biotech Corp | Uso terapeutico de anticuerpos del receptor anti-tweak. |
| US8093006B2 (en) | 2009-04-02 | 2012-01-10 | Hoffmann-La Roche Inc. | Antibodies against human tweak and uses thereof |
| US20120055055A1 (en) * | 2010-09-02 | 2012-03-08 | Illumin8 Outdoor Media, LLC | Systems and Method for Outdoor Media Signage |
| WO2012045671A1 (en) * | 2010-10-05 | 2012-04-12 | F. Hoffmann-La Roche Ag | Antibodies against human tweak and uses thereof |
| JP5832559B2 (ja) * | 2011-03-10 | 2015-12-16 | オメロス コーポレーション | ｅｘｖｉｖｏにおける加速された抗体進化による抗ＦＮ１４モノクローナル抗体の生成 |
| JP2016000003A (ja) * | 2013-04-19 | 2016-01-07 | アステラス製薬株式会社 | 新規抗ヒトｔｗｅａｋ抗体 |
| CN105779576B (zh) * | 2014-12-25 | 2025-01-17 | 中国人民解放军第四军医大学 | 人tnfrsf12a基因的用途及其相关药物 |
| US10994017B2 (en) | 2016-12-02 | 2021-05-04 | Avelas Biosciences, Inc. | Nerve labeling compositions and uses thereof |
| MY204672A (en) | 2018-10-31 | 2024-09-09 | Astellas Pharma Inc | Anti-human fn14 antibody |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998035061A2 (en) * | 1997-02-12 | 1998-08-13 | Abbott Laboratories | Member of the tnf family useful for treatment and diagnosis of disease |
| HUP0105044A3 (en) * | 1999-01-15 | 2004-07-28 | Biogen Inc Cambridge | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| EP1626058B1 (en) * | 1999-03-08 | 2007-10-31 | Genentech, Inc. | Compositions and methods for the diagnosis of tumour |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| EP2298334A3 (en) * | 1999-12-20 | 2012-04-04 | Immunex Corporation | Tweak receptor |
| US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
| CA2422095A1 (en) * | 2000-09-14 | 2002-03-21 | Biogen, Inc. | Tweak receptor agonists as anti-angiogenic agents |
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| CA2587018A1 (en) * | 2004-11-08 | 2006-05-18 | University Of Maryland, Baltimore | Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| KR20130089271A (ko) * | 2005-03-07 | 2013-08-09 | 제넨테크, 인크. | Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물 |
-
2006
- 2006-03-02 KR KR1020137015784A patent/KR20130089271A/ko not_active Withdrawn
- 2006-03-02 BR BRPI0608012-0A patent/BRPI0608012A2/pt not_active Application Discontinuation
- 2006-03-02 AU AU2006220825A patent/AU2006220825A1/en not_active Abandoned
- 2006-03-02 CA CA002597485A patent/CA2597485A1/en not_active Abandoned
- 2006-03-02 KR KR20157002807A patent/KR20150031459A/ko not_active Ceased
- 2006-03-02 CN CNA2006800155970A patent/CN101171035A/zh active Pending
- 2006-03-02 RU RU2007137060/14A patent/RU2007137060A/ru unknown
- 2006-03-02 CN CN2011101610523A patent/CN102225200A/zh active Pending
- 2006-03-02 WO PCT/US2006/007547 patent/WO2006096487A2/en not_active Ceased
- 2006-03-02 US US11/908,074 patent/US20080286271A1/en not_active Abandoned
- 2006-03-02 ZA ZA200707489A patent/ZA200707489B/xx unknown
- 2006-03-02 KR KR1020077020346A patent/KR20070108537A/ko not_active Withdrawn
- 2006-03-02 JP JP2008500768A patent/JP2008531746A/ja not_active Withdrawn
- 2006-03-02 EP EP06736808.4A patent/EP1853312B1/en not_active Revoked
-
2007
- 2007-08-09 IL IL185180A patent/IL185180A0/en unknown
-
2011
- 2011-11-21 US US13/300,897 patent/US20120269808A1/en not_active Abandoned
-
2013
- 2013-12-27 JP JP2013271694A patent/JP2014111605A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008531746A5 (cg-RX-API-DMAC7.html) | ||
| Steeland et al. | A new venue of TNF targeting | |
| JP6901493B2 (ja) | 抗ｂｃｍａポリペプチド及びタンパク質 | |
| CA2386463C (en) | April receptor (bcma) and uses thereof | |
| JP5837730B2 (ja) | 抗インターフェロンアルファモノクローナル抗体及び使用方法 | |
| CA3108915A1 (en) | Proteins binding nkg2d, cd16 and a tumor-associated antigen | |
| CA2558371C (en) | Methods of modulating immune responses by modulating tim-1 and tim-4 function | |
| PL207501B1 (pl) | Zastosowanie polipeptydu BCMA oraz przeciwciała skierowanego przeciwko BCMA | |
| Dubree et al. | Selective α4β7 integrin antagonists and their potential as antiinflammatory agents | |
| Benucci et al. | Tumor necrosis factors blocking agents: analogies and differences | |
| CN101675078A (zh) | CRIg拮抗剂 | |
| KR20190115042A (ko) | 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법 | |
| US11773177B2 (en) | Variant antibodies that bind OX40 | |
| US20220288226A1 (en) | Methods and compositions to treat autoimmune diseases and cancer | |
| CN116847887A (zh) | 治疗自身免疫性疾病和癌症的方法和组合物 | |
| RU2007137060A (ru) | Способы и композиции для модуляции активности tweak и fn14 | |
| TW200948377A (en) | Affinity matured CRIg variants | |
| TW202336035A (zh) | 治療自體免疫疾病及癌症之方法及組成物 | |
| WO2010081787A1 (en) | IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS | |
| Scheinberg et al. | The potential role of blisibimod for the treatment of systemic lupus erythematosus | |
| CN101371923B (zh) | Baff受体(bcma),一种免疫调节剂 | |
| HK40000997A (en) | Pan-elr+ cxc chemokine antibodies | |
| HK40000997B (en) | Pan-elr+ cxc chemokine antibodies | |
| Das | Characterisation of heteromers and oligomers in the TNF family of ligands and receptors |